The immense growth and rapid development in the biopharmaceutical segment pose miscellaneous challenges. With their remarkable therapeutic benefits, biopharmaceuticals have the potential to improve patients’ lives all over the world. A number of previously incurable diseases can now be cured, or at least treated. The life expectancy and quality of life have improved for patients with diseases like multiple sclerosis, cancer and arthritis. And more and more rare diseases can be addressed with increasingly specialized drugs.
Biopharmaceutical activities are on the rise in many pharmaceutical companies – in fact biotech and vaccines have been a major driver of the wave of mergers and acquisitions in recent years. And we expect the changes in biopharmaceutical manufacturing to continue. Old as well as new large –molecule products are being produced in increased titers and often decreased batch sizes.
At Integrated Project Services (IPS), we see the new manufacturing paradigm of combining new single-use biotech technology with proven stainless steel solutions as challenging and interesting area. Actually, new products produced in smaller volumes will ultimately develop into personalized drugs. New, smaller and more flexible multiproduct facilities are becoming popular as adaptability becomes a business plan prerequisite and the significant capital costs of first generation facilities become prohibitive and personalized medicines that target smaller patient groups are uniting with single-use technology.
Biopharmaceuticals and aseptic processing were the roots of our business and have been our core expertise throughout the years.